Systematic Evidence-Based Analysis of Plaque Injection Therapy for Peyronie's Disease

Russell, Shane T.; Steers, William D.; McVary, Kevin T.

doi:10.1016/j.eururo.2006.10.042

Cited by 53 publications

(36 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, these trials are often unclear as to whether the patients under evaluation include those in the early (acute) phase, the late fibrotic (stable) phase, or a combination of patients of both phases. Treatment in the early inflammatory phase can theoretically reduce the degree of inflammation and break the cycle of fibrin deposition and abnormal tissue remodelling [Russell et al 2007]. Further evaluation regarding the effect of treatment in patients with PD in AP (< 12 months) should be conducted.…”

Section: Discussionmentioning

confidence: 99%

Experience in the use of collagenase clostridium histolyticum in the management of Peyronie’s disease: current data and future prospects

Rojo

Iribarren

Carballido-Rodríguez

et al. 2014

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Introduction: Peyronie's disease (PD) is a chronic wound-healing disorder characterized by formation of fibrous inelastic scarring of the tunica albuginea resulting in a variety of penile deformities. In most cases, PD is accompanied by a physical and psychological impact. Xiaflex ® is an injectable collagenase clostridium histolyticum (CCh) preparation consisting of a predetermined mixture of two distinct collagenases. Recently the US Food and Drug Administration (FDA) approved Xiaflex ® for the nonsurgical treatment of men with PD with curvature of 30° or more and tangible scar tissue plaque in their penis. Method: This article presents a comprehensive review of the updated information on the use of Xiaflex ® for the nonsurgical treatment of PD. Results: Mean improvements in penile curvature ranging from 29% to 34% and in bother domain scores have been reported. The majority of the reported adverse effects are mild or moderate and 79% resolve without intervention. Conclusion: The combined results of these trials have led to the FDA approval of CCh for the treatment of PD. However, the long-term effects and results need further investigation, with large follow-up series. Considering these results, future perspectives will probably result in the use of a combined or sequential therapy including CCh.

show abstract

Section: Discussionmentioning

confidence: 99%

Experience in the use of collagenase clostridium histolyticum in the management of Peyronie’s disease: current data and future prospects

Rojo

Iribarren

Carballido-Rodríguez

et al. 2014

Therapeutic Advances in Urology

View full text Add to dashboard Cite

show abstract

“…No medical treatment that can relieve all symptoms in patients with Peyronie's disease is currently available. The efficacy of multiple intralesional therapy has been proved in a single blind, multicentre, placebo-controlled study [15]. Peyronie's disease is a disorder of the penile tunica albuginea characterized by development of a fibrotic plaque.…”

Section: Discussionmentioning

confidence: 99%

A Preliminary Study on Possible Effects of Mitomycin-C on the Collagen Content of Penis in Rat

Hosseini¹,

Mohseni²,

Alizadeh³

2016

UNOAJ

View full text Add to dashboard Cite

“…Les études sur les injections dans la plaque sont très anciennes mais ont presque toujours eu un niveau de preuve faible [32].…”

Section: Traitements Mé Dicamenteux Locauxunclassified

Maladie de La Peyronie: connaissances validées et hypothèses en physiopathologie, épidémiologie, diagnostic et thérapeutique

et al. 2007

View full text Add to dashboard Cite

Objet : La maladie de La Peyronie est décrite depuis plus de deux cents ans, mais elle demeure encore mal comprise. Cela explique le foisonnement d'hypothèses étiopathogéniques, même si aujourd'hui un certain consensus émerge.Mé thodes : Les grandes études reconnues et les conférences sur le sujet ont servi de base pour décrire la maladie de La Peyronie. Une revue systématique et presque exhaustive de la littérature depuis 2004 a été réalisée et a permis, avec l'expérience du service, de dégager les tendances actuelles.Résultats : Sur le plan étiopathogénique, l'hypothèse des microtraumatismes reste d'actualité mais n'est pas suffisante et les hypothèses auto-immune, génétique et vasculaire semblent actuellement valables. Il n'y a pas d'examens complémentaires nécessaires en pratique courante. Les traitements médicaux sont très nombreux et ont surtout fait la preuve de leur efficacité sur la douleur. On retiendra la vitamine E, la colchicine ainsi que les injections intraplaques de corticoïdes ou de vérapamil. Des traitements prometteurs par inhibiteurs de la phosphodiestérase de type 5 ou par injection d'interféron B doivent être validés. Les traitements chirurgicaux de correction de la courbure et des troubles de l'érection ne seront proposés que si la courbure est stabilisée depuis six mois. La qualité des érections, la taille de la verge, l'importance de la courbure et les souhaits du patient seront les éléments permettant de prendre la bonne décision thérapeutique. La correction de la courbure par la technique de Nesbit reste la technique de référence. En cas de plaque très importante et de troubles de l'érection, la section de la plaque avec greffe veineuse et prothèse gonflable est actuellement la meilleure technique. On citera la technique de Leriche, la mise en place d'implants souples et la lithotritie extra-corporelle comme possibles techniques d'avenir. Mots clés : La Peyronie -Chirurgie -Courbure -VergeDouleurPeyronie's disease: evidence-based knowledge and hypotheses in its pathophysiology, epidemiology, diagnosis and treatment Abstract: Subject: Although still poorly understood, La Peyronie's disease has been described for two hundred years. This lack of solid knowledge explains the existence of so many etiopathogenic hypotheses, despite the current emerging consensus.Method: We performed an exhaustive review of the major studies and conference reports on La Peyronie's disease since 2004 to determine present thinking on this condition.Results: The microtrauma hypothesis remains valid today but is not comprehensive enough to fully explain aetiology; explanations touching on autoimmunity, genetics and the vascular system are necessary to better understand the disease. Clinical examination suffices for establishing diagnosis. Medical treatment has mostly succeeded in managing pain. Vitamin E, colchicine, steroid and intraplaque verapamil injections are now accepted treatments. Further studies are needed to determine the efficacy of treatment with phosphodiesterase type 5 or beta interferon intraplaque...

show abstract

Systematic Evidence-Based Analysis of Plaque Injection Therapy for Peyronie's Disease

Cited by 53 publications

References 54 publications

Experience in the use of collagenase clostridium histolyticum in the management of Peyronie’s disease: current data and future prospects

Experience in the use of collagenase clostridium histolyticum in the management of Peyronie’s disease: current data and future prospects

A Preliminary Study on Possible Effects of Mitomycin-C on the Collagen Content of Penis in Rat

Maladie de La Peyronie: connaissances validées et hypothèses en physiopathologie, épidémiologie, diagnostic et thérapeutique

Contact Info

Product

Resources

About